The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAs analysts recalibrate investment portfolios within the immunology and financial sectors, HSBC has issued a notably bullish outlook for AbbVie (ABBV), raising its price target to $300 with a Buy rating. This follows Cantor Fitzgerald's target increase to $265 for the same stock, while JP Morgan raised its target for Citizens Financial Group (CFG) to $76.00. Conversely, BMO Capital significantly lowered its price target for Dow Inc from $46.00 to $33.00 due to fluctuating market conditions.
These adjustments occur as pharmaceutical peers like Amgen (AMGN) show relative stability, with its stock closing at $374.15 per market data on July 2, 2026. Compared to previous quarter results, researchers are attempting to pin down fair value for healthcare firms amid pricing pressures, while the regional banking sector remains under scrutiny for net interest margins. Experts suggest the downgrade for Dow Inc reflects broader concerns regarding global industrial demand and raw material costs.
Regarding current price levels, ABBV closed at $261.07 and CFG at $70.98 (as of July 2, 2026). Investors should watch for upcoming macroeconomic data, including manufacturing PMI reports which could further impact basic materials stocks, as well as any regulatory updates affecting the biotechnology and pharmaceutical sectors.